{
  "report_rows": [
    {
      "kpi": "Diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.30 vs. cons $1.28",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating income",
      "prediction": "BEAT",
      "answer": "pred ~$292m vs. cons $286m",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating revenue",
      "prediction": "BEAT",
      "answer": "pred ~$925m vs. cons $902m",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 diluted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$8.45 midpoint vs. cons $8.45 midpoint (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 capital-expenditure plan",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4.20bn vs. cons $4.20bn (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Texas Rule 7.7102 pretax benefit",
      "prediction": "UNCHANGED",
      "answer": "guide ~$160m vs. cons $160m (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "APT through-system contribution",
      "prediction": "UNCHANGED",
      "answer": "guide ~$0.10 EPS vs. cons $0.10 EPS (2H FY26)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.5,
  "day5_path": "STABILIZE",
  "day5_rationale": "A ~$1.30 EPS result versus $1.28 consensus and intact regulatory/APT commentary support a modest initial gain, but unchanged ~$8.45 FY26 midpoint guidance versus $8.45 consensus leaves FY27 out-period EPS math broadly intact rather than driving material estimate revisions.",
  "day5_confidence": "MEDIUM"
}